There is a very common story in medicine, and it goes like this. At forty-five, a blood test comes back with a fasting glucose that is a little too high and an LDL that is a little too high. Metformin is started. A statin is added. The numbers improve. Everyone is satisfied.
At fifty-two, the numbers have drifted again. The metformin dose goes up. At fifty-eight, a second agent is added. At sixty-three, despite a decade of perfect adherence, there is a stent.
Nothing went wrong in that story. Every prescription was correct. The patient did everything asked of them. And yet the destination was never really in doubt, because the entire strategy was built on managing two sets of numbers rather than repairing two systems. Metformin makes the liver less enthusiastic about producing glucose. A statin makes the liver produce less cholesterol. Both are genuinely useful. Neither one asks the tissue to work properly again.
This matters because metabolic disease and cardiovascular disease are not a sequence, with one leading politely to the other. They are two failures happening at once, in two different places, each one accelerating the other. And until recently, we have had no way to address the second one at all.
The first failure: how the body handles fuel
The metabolic half is the one most people understand, because it is the one their blood test measures. Fat accumulates in the liver. Muscle becomes less responsive to insulin. The pancreas compensates by producing more. Triglycerides climb. Adipose tissue, particularly visceral fat, stops behaving like storage and starts behaving like an inflamed organ, releasing a steady stream of signals into the circulation.
FGF21 is the body’s own regulator for exactly this situation. It is a hormone released chiefly by the liver under metabolic stress, and it acts across the whole body: it pushes the liver toward burning fat rather than storing it, improves how muscle and fat respond to insulin, and raises adiponectin, the protective adipose hormone that falls as metabolic health declines.
What makes FGF21 interesting is not the theory but the clinical evidence, which is now substantial. Across randomized controlled trials in overweight and obese adults, FGF21 analogs produced significant reductions in triglycerides, total cholesterol and LDL cholesterol, together with marked increases in HDL cholesterol and circulating adiponectin.1 In patients with severe hypertriglyceridemia, one analog cut triglycerides by more than half against placebo, reduced apolipoprotein B and non-HDL cholesterol, and reduced liver fat fraction by 42% on MRI over just eight weeks.2
Read that list again with a lipid panel in your hand. Triglycerides down, LDL down, HDL up, apoB down, liver fat down. These are the same lines a statin is fighting — but reached by changing how the liver and adipose tissue handle fuel, rather than by blocking a single synthetic enzyme.
One honest note, because it matters: in those same trials, fasting glucose and fasting insulin did not change significantly.1 FGF21 is not a glucose-lowering drug in the way metformin is. It works upstream, on lipid handling, liver fat and adipose signaling, which is precisely why it is complementary to what most patients are already taking rather than a replacement for it.
The second failure: the vessel wall
Here is the part conventional care leaves almost entirely untouched.
While the metabolic machinery is struggling, something separate is happening in the blood vessels themselves. The endothelium — the single living cell layer lining every artery — loses its ability to produce nitric oxide on demand. Vessels stiffen. Small vessels are lost, so perfusion of the tissue behind them falls. Immune cells begin infiltrating the vessel wall, and plaque forms.
You can normalize every number on a blood panel and leave all of this in place. That is the gap.
The interesting thing about this gap is how we learned to address it. Some people reach ninety-five and beyond without ever developing significant cardiovascular disease. A research group in Italy, led by Annibale Puca, studied these long-lived individuals and identified a variant of a gene called BPIFB4 that they carry far more often than the rest of the population — the longevity-associated variant, or LAV-BPIFB4.
Then they did the obvious experiment: transfer the gene and see what happens.
BPIFB4 encodes a secreted protein that enhances endothelial function through activation of endothelial nitric oxide synthase, and the longevity variant has shown protection against hypertension, atherosclerosis, diabetic cardiomyopathy, frailty and inflammaging.3 In atherosclerotic mice on a high-fat diet, a single systemic transfer of LAV-BPIFB4 reduced endothelial dysfunction, halted the formation of vascular plaques and reduced macrophage infiltration into the vessel wall.4 In aging hearts, it supported cardiac function and vascularization, with the same genotype in humans associated with better preservation of the small-vessel pericyte coverage that is lost in failing elderly hearts.5 And in humans, carrying the longevity variant is associated with reduced frailty, with endothelial dysfunction understood as one of the mechanisms underlying frailty itself.6
Note what this is not. It is not a synthetic molecule designed to push a pathway toward a guessed-at optimum. It is a version of a human gene that a subset of human beings already runs — and whose phenotype we can observe directly in the people who carry it. They are the ones who reach a hundred without a cardiology file.
Why the combination is the point
Now put the two together, and the logic becomes clear.
FGF21 addresses what is circulating: the lipid load, the liver fat, the adipose inflammation, the insulin signaling. LAV-BPIFB4 addresses what is receiving: the endothelium, nitric oxide availability, small-vessel density, the immune behavior of the vessel wall.
Each one, alone, is limited by the state of the other. Correct the metabolism of a patient whose endothelium is stiff and inflamed and you have improved a blood test while leaving the mechanism of the eventual event intact. Repair the endothelium of a patient still bathing their tissues in excess lipid and inflammatory adipokines and you have repaired something that will be damaged again.
And these two are not parallel lines that never touch. Adipose inflammation is one of the direct drivers of endothelial injury — a point demonstrated with LAV-BPIFB4 itself, where the longevity protein reduced adipose tissue-derived mediators of systemic inflammation and preserved endothelial function in atherosclerotic mice on a high-fat diet.7 FGF21 acts on that adipose tissue from the metabolic side while LAV-BPIFB4 protects the vessel from the vascular side. They meet in the middle.
This is why we think of them as one intervention with two arms rather than two products in a catalogue.
What this looks like at Blast
Both are delivered as Blast Gene Therapy: non-viral, non-integrating constructs with no bacterial backbone, administered into subcutaneous fat, from which the expressed protein acts systemically. There is no viral vector and nothing inserted into your genome. The construct instructs your own cells to produce the protein, and it is your own tissue doing the work.
Both are given at the end of a program rather than the beginning. Our pluripotent products do the repair work on site while the client is with us; the gene therapies reinforce and extend that work after they have gone home. The sequence is deliberate — reinforcement after repair, not instead of it.
A word to the person who has been on this regimen for ten years
If you have been taking metformin and a statin since your forties, you have probably noticed the shape of the thing: the doses only ever move in one direction, and no one has ever mentioned an endpoint.
Let us be precise about what we are and are not saying. Nothing here is a reason to stop or reduce a medication your physician has prescribed, and any change to your regimen is a conversation to have with them, based on your own numbers over time. The clinical evidence cited above comes from trials of pharmaceutical FGF21 analogs and from preclinical and human genetic work on LAV-BPIFB4; it establishes the biology, not a guaranteed outcome for any individual.
What we are saying is that the underlying strategy is different. For ten years the approach has been to suppress two outputs a little harder each year. The approach described here is to improve how the liver and adipose tissue handle fuel, and to give the vessel wall the same protein that people who age without cardiovascular disease produce naturally. Those are repairs rather than suppressions. And a patient whose metabolism and vasculature are genuinely functioning better is, at minimum, a patient whose ladder of escalating doses has a reason to stop climbing.
References
- Nie et al. Effects and safety of FGF21 analogs on glycemic parameters, lipid profiles, and adiponectin in overweight and obese adults: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2025.
- Bhatt et al. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial (ENTRIGUE). Nat Med. 2023.
- Dossena et al. New insights for BPIFB4 in cardiovascular therapy. Int J Mol Sci. 2020;21(19):7163.
- Puca et al. Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. Eur Heart J. 2020;41(26):2487–97.
- Cattaneo et al. The longevity-associated BPIFB4 gene supports cardiac function and vascularization in ageing cardiomyopathy. Cardiovasc Res. 2023.
- Malavolta et al. LAV-BPIFB4 associates with reduced frailty in humans and its transfer prevents frailty progression in old mice. Aging (Albany NY). 2019;11(16).
- Ciccarelli et al. In vivo evidence supporting the effectiveness of LAV-BPIFB4 in reducing adipose tissue-derived mediators of systemic inflammation. 2025.
- Villa et al. Genetic analysis reveals a longevity-associated protein modulating endothelial function and angiogenesis. Circ Res. 2015;117(4):333–45.
